NanoAssemblr™ GMP System

Overview

The NanoAssemblr™ GMP System is a fully integrated, turnkey microfluidic platform engineered for the clinical-scale manufacturing of lipid nanoparticle (LNP) formulations under Good Manufacturing Practice (GMP) conditions. It leverages Cytiva’s proprietary NxGen™ mixing technology—a laminar-flow-based, deterministic microfluidic architecture—to achieve precise, reproducible, and scalable nucleic acid encapsulation. Unlike turbulent or chaotic mixing approaches, NxGen™ employs a geometrically defined annular mixing chamber that ensures consistent residence time distribution, interfacial contact area, and shear history across operating flow rates. This enables robust control over critical process parameters (CPPs) such as mixing ratio, flow rate ratio, total flow rate, and temperature—directly influencing critical quality attributes (CQAs) including particle size (Z-average), polydispersity index (PDI), encapsulation efficiency (EE%), and nucleic acid integrity. Designed specifically for Phase I and Phase II clinical supply, the system operates within a closed, single-use fluidic pathway to eliminate cross-contamination risks and support rapid tech transfer from preclinical development to GMP production.

Key Features

• Single-Use GMP Fluidic Pathway: Pre-sterilized, gamma-irradiated disposable kits include NxGen™ mixing chips, tubing assemblies, pump heads, and connectors—each accompanied by full material traceability documentation (e.g., USP Class VI compliance, extractables & leachables data) and lot-specific certificates of conformance.
• Integrated Online Dilution Module: Enables automated post-mixing buffer exchange and stepwise dilution in real time, minimizing aggregation, stabilizing particle morphology, and reducing downstream formulation hold times.
• NxGen™ Scalable Mixing Architecture: Maintains identical hydrodynamic mixing conditions across platforms—from benchtop Ignite+™ (preclinical) to NanoAssemblr™ GMP System (clinical) and commercial-scale systems—enabling direct CPP transfer without re-optimization.
• GMP-Ready Documentation Package: Includes validated standard operating procedures (SOPs), installation qualification (IQ), operational qualification (OQ), performance qualification (PQ) protocols, and electronic batch records (EBR)-compatible data templates aligned with FDA 21 CFR Part 11 and EU Annex 11 requirements.
• Modular Pumping & Control System: Dual-syringe or peristaltic pump configurations support precise volumetric delivery of aqueous (nucleic acid) and organic (lipid) phases; flow rates are programmable from 60 to 200 mL/min with ≤±1.5% volumetric accuracy.

Sample Compatibility & Compliance

The NanoAssemblr™ GMP System is qualified for processing mRNA, self-amplifying RNA (saRNA), siRNA, and DNA payloads encapsulated in ionizable cationic lipids, PEGylated lipids, cholesterol, and helper phospholipids. All wetted materials comply with ISO 10993-5 (cytotoxicity), USP and (biological reactivity), and ISO 11137 (sterilization validation). The system supports alignment with ICH Q5A(R2), Q5B, Q5D, and Q5E for biotechnological product characterization, and its operational design facilitates adherence to EMA Guideline on Quality of RNA-Based Therapeutics and FDA Guidance for Industry: Human Gene Therapy for Rare Diseases. Process validation studies confirm equivalence of CQAs—including Z-average diameter (95–110 nm), PDI (92%)—across scale-up transitions from Ignite+™ to GMP System using saRNA-LNPs.

Software & Data Management

The system operates via Cytiva’s GMP-compliant control software with audit-trail-enabled event logging, user role-based access control (RBAC), and electronic signature functionality compliant with 21 CFR Part 11. All process parameters—including individual phase flow rates, total flow, mixing ratio, temperature setpoints, and run duration—are recorded at ≥1 Hz resolution and exported in CSV or PDF formats compatible with laboratory information management systems (LIMS) and enterprise quality management systems (eQMS). Raw sensor data (pressure, temperature, flow) is retained for ≥15 years per internal retention policy, supporting regulatory inspections and root cause analysis during deviation investigations.

Applications

• Clinical supply of LNP-formulated mRNA vaccines and therapeutics (e.g., SARS-CoV-2, influenza, cancer neoantigens)
• Process development and tech transfer for autologous and allogeneic cell therapy vectors
• Manufacturing of LNP-based gene editing reagents (e.g., Cas9 mRNA + sgRNA co-encapsulation)
• Scale-down modeling for commercial process validation and comparability studies
• Supporting IND-enabling toxicology and biodistribution studies with GMP-grade material

FAQ

Is the NanoAssemblr™ GMP System compliant with FDA 21 CFR Part 11 and EU Annex 11?
Yes—the system includes electronic signature capability, immutable audit trails, and RBAC configuration validated per Part 11 Annex A and Annex 11 Section 4.2.
Can process parameters be transferred directly from Ignite+™ to the GMP System?
Yes—NxGen™ technology preserves identical mixing kinetics; CPPs such as flow rate ratio and total flow are directly translatable without re-optimization.
What documentation is provided for regulatory submissions?
Full GMP documentation package includes IQ/OQ/PQ protocols, SOPs, material traceability reports, and validation summaries aligned with ICH M4Q(R2) and FDA CMC guidance.
Are the disposable fluidic kits pre-qualified for endotoxin and bioburden?
Yes—all kits undergo rigorous endotoxin testing (<0.25 EU/mL) and bioburden assessment per ISO 11737-1, with full test reports supplied per lot.
Does the system support integration with upstream plasmid or mRNA synthesis platforms?
Yes—standardized 1/4″-28 UNF ports and analog/digital I/O interfaces enable seamless integration with IVT reactors, tangential flow filtration (TFF) units, and ultrafiltration/diafiltration systems.